Immunovant Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2023	2022	2021	2020	2019	2018
Net Income	-259.34	-210.96	-156.73	-107.43	-66.39	Upgrade
Depreciation & Amortization	1.36	1.32	1.23	1	0.02	Upgrade
Share-Based Compensation	41.12	32.3	34.24	18.82	6.96	Upgrade
Other Operating Activities	2.63	-10.85	15.14	4.28	6.05	Upgrade
Operating Cash Flow	-214.23	-188.19	-106.11	-83.33	-53.36	Upgrade
Capital Expenditures	-0.36	-0.2	-0.25	-0.21	-0.03	Upgrade
Investing Cash Flow	-0.36	-0.2	-0.25	-0.21	-0.03	Upgrade
Share Issuance / Repurchase	478.44	71.16	0.13	387.54	1.16	Upgrade
Debt Issued / Paid	0	0	0	-3.19	37.91	Upgrade
Other Financing Activities	-6.01	-0.27	200	-1.24	107.91	Upgrade
Financing Cash Flow	472.43	70.89	200.13	383.11	146.97	Upgrade
Exchange Rate Effect	0.99	0.22	-0.09	0	0	Upgrade
Net Cash Flow	258.83	-117.29	93.67	299.58	93.59	Upgrade
Free Cash Flow	-214.59	-188.39	-106.37	-83.54	-53.39	Upgrade
Free Cash Flow Per Share	-1.55	-1.53	-0.97	-0.95	-1.24	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).